A new generation of RNA Therapeutics

Overcoming RNA therapies limitations

Traditional RNA therapies have an ‘Achilles heel’ – they struggle to get inside the cells where their targets reside

rna_therapy_img

The ‘delivery challenge’ has limited the number of diseases for which RNA therapies have been successfully created

PYC's RNA delivery platform effectively addresses this predominant issue by ensuring a sufficient amount of the drug is delivered to its target

rna_therapy_img

PYC combines existing RNA drug design technology with its proprietary drug delivery platform to create next generation RNA therapeutics

rna_therapy_img

PYC's delivery platform is used to assist the RNA drug reach its target inside the target cell

What makes PYC's delivery technology superior

PYC’s non-viral drug delivery platform and scalable delivery technology addresses the fundamental challenge of RNA drugs – sufficient delivery to the target cell.

Solving this challenge extends the reach of RNA therapies to new disease indications.

PYC’s PPMO is ~100-fold more effective at reaching the target cell in vivo than ‘naked’ 2’MOE RNA drugs

What makes PYC's delivery technology superior